Pharmaceuticals in the Netherlands

Pharmaceuticals in the Netherlands


  • Products Id :- OHMF4496
  • |
  • Pages: 41
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Pharmaceuticals in the Netherlands

Summary

Pharmaceuticals in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Netherlands pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

- The Dutch pharmaceuticals market had total revenues of USD 5.1bn in 2017, representing a compound annual rate of change (CARC) of -2.7% between 2013 and 2017.

- The Ministry of Health, Welfare and Sport sets maximum allowable prices for medicines in accordance with the Medicine Prices Act. When buying in drugs, pharmacists may not pay more than the maximum prices.

- Generics substitution at the pharmacy level and prescribing drugs by their International Non-proprietary Name (INN) are allowed and indeed actively encouraged in the Netherlands. These cost saving measures disrupts the ability of the market to produce growth.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in the Netherlands

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in the Netherlands

- Leading company profiles reveal details of key pharmaceuticals market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands pharmaceuticals market with five year forecasts

Reasons to buy

- What was the size of the Netherlands pharmaceuticals market by value in 2017?

- What will be the size of the Netherlands pharmaceuticals market in 2022?

- What factors are affecting the strength of competition in the Netherlands pharmaceuticals market?

- How has the market performed over the last five years?

- Who are the top competitiors in the Netherlands's pharmaceuticals market?



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Executive Summary 2

Market value 2

Market value forecast 2

Geography segmentation 2

Market share 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 9

Market value 9

Market Segmentation 10

Geography segmentation 10

Market share 11

Market Outlook 12

Market value forecast 12

Five Forces Analysis 13

Summary 13

Buyer power 14

Supplier power 16

New entrants 17

Threat of substitutes 19

Degree of rivalry 20

Leading Companies 22

AstraZeneca PLC 22

GlaxoSmithKline Plc 25

Novartis AG 29

Pfizer Inc. 32

Macroeconomic Indicators 36

Country data 36

Methodology 38

Industry associations 39

Related MarketLine research 39

Appendix 40

About MarketLine 40

List of Figures

Figure 1: Netherlands pharmaceuticals market value: USD billion, 2013-17

Figure 2: Netherlands pharmaceuticals market geography segmentation: % share, by value, 2017

Figure 3: Netherlands pharmaceuticals market share: % share, by value, 2017

Figure 4: Netherlands pharmaceuticals market value forecast: USD billion, 2017-22

Figure 5: Forces driving competition in the pharmaceuticals market in the Netherlands, 2017

Figure 6: Drivers of buyer power in the pharmaceuticals market in the Netherlands, 2017

Figure 7: Drivers of supplier power in the pharmaceuticals market in the Netherlands, 2017

Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the Netherlands, 2017

Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in the Netherlands, 2017

Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in the Netherlands, 2017

Figure 11: AstraZeneca PLC: revenues & profitability

Figure 12: AstraZeneca PLC: assets & liabilities

Figure 13: GlaxoSmithKline Plc: revenues & profitability

Figure 14: GlaxoSmithKline Plc: assets & liabilities

Figure 15: Novartis AG: revenues & profitability

Figure 16: Novartis AG: assets & liabilities

Figure 17: Pfizer Inc.: revenues & profitability

Figure 18: Pfizer Inc.: assets & liabilities

List of Tables

Table 1: Netherlands pharmaceuticals market value: USD billion, 2013-17

Table 2: Netherlands pharmaceuticals market geography segmentation: USD billion, 2017

Table 3: Netherlands pharmaceuticals market share: % share, by value, 2017

Table 4: Netherlands pharmaceuticals market value forecast: USD billion, 2017-22

Table 5: AstraZeneca PLC: key facts

Table 6: AstraZeneca PLC: key financials (USD )

Table 7: AstraZeneca PLC: key financial ratios

Table 8: GlaxoSmithKline Plc: key facts

Table 9: GlaxoSmithKline Plc: key financials (USD )

Table 10: GlaxoSmithKline Plc: key financials (GBP)

Table 11: GlaxoSmithKline Plc: key financial ratios

Table 12: Novartis AG: key facts

Table 13: Novartis AG: key financials (USD )

Table 14: Novartis AG: key financial ratios

Table 15: Pfizer Inc.: key facts

Table 16: Pfizer Inc.: key financials (USD )

Table 17: Pfizer Inc.: key financial ratios

Table 18: Netherlands size of population (million), 2013-17

Table 19: Netherlands gdp (constant 2005 prices, USD billion), 2013-17

Table 20: Netherlands gdp (current prices, USD billion), 2013-17

Table 21: Netherlands inflation, 2013-17

Table 22: Netherlands consumer price index (absolute), 2013-17

Table 23: Netherlands exchange rate, 2013-17

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license
Single User License
USD 350 INR 24941
Site License
USD 700 INR 49882
Corporate User License
USD 1050 INR 74823

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com